Randomised controlled tiral (RCT) detail
Studies | |
Number of RCTs | 127/147 (86.4) |
Number of pilot studies | 13/147 (8.8) |
Number of RCT protocols | 7/147 (4.8) |
World region for recruitment | |
Asia | 54/147 (36.7) |
North America | 36/147 (24.5) |
Europe | 26/147 (17.7) |
Africa | 15/147 (8.5) |
Latin America | 1/147 (0.7) |
Australasia | 15/147 (8.5) |
Year published | |
2012 | 26/147 (17.8) |
2013 | 24/147 (16.3) |
2014 | 24/147 (16.3) |
2015 | 33/147 (22.4) |
2016 | 40/147 (27.2) |
Number of sites | |
1 | 132/147 (89.8) |
2–3 | 9/147 (6.1) |
4–5 | 2/147 (1.4) |
>5 | 4/147 (2.7) |
Number of participants in full RCTs | |
<10 | 4/127 (3.1) |
11–50 | 62/127 (48.8) |
51–100 | 39/127 (30.7) |
101–150 | 11/127 (8.7) |
>150 | 11/127 (8.7) |
Participants recruited | |
<18 years | 24/147 (16.3) |
>18 years | 59/147 (40.1) |
Mixed age range | 25/147 (17.0) |
Not stated | 34/147 (23.1) |
N/A (protocol)‡ | 5/147 (3.4) |
Type of intervention | |
Dressings and wound care | 38/147 (25.9) |
Surgical technique | 19/147 (12.9) |
Treatment of pain or itch* | 16/147 (10.9) |
Impact of exercise and rehabilitation | 13/147 (8.8) |
Intensive care management | 10/147 (6.8) |
Treatment of hypermetabolism | 8/147 (5.4) |
Nutrition | 8/147 (5.4) |
Scar management | 7/147 (4.8) |
Treatment of inhalational injury | 3/147 (2.0) |
Use of topical rHGM | 3/147 (2.0) |
Use of rHGH | 3/147 (2.0) |
Sugar management | 2/148 (2.0) |
Treatment of infection | 2/147 (1.4) |
Treatment of DVT | 2/147 (1.4) |
Blood management | 2/147 (1.4) |
Extracorporeal shock wave therapy | 2/147 (1.4) |
Platelet-rich plasma use | 2/147 (1.4) |
Others† | 7/147 (5.4) |
*Inc. distraction for dressing changes.
†Inc. levamisole, hyperbaric oxygen, fibroblast growth factor, oral calcium use, ketoconazole, low intensity laser.
‡No participants reported as study is a protocol.
DVT, deep vein thrombosis; N/A, not applicable; rHGH, recombinant human growth hormone; rHGM, recombinant Human Granulocyte-Macrophage colony-stimulating factor.